ArticleCurrent microbiology2022
Virulence Profiles and Antimicrobial Resistance of Streptococcus agalactiae Infective and Colonizing Strains from Argentina.
Article in Current microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Global patterns of antibiotic resistance in group BFrontiers in microbiology · 2025Pooled it
- Invasive Streptococcus agalactiae infections in infants in Guangzhou, Southern China (2013-2022): molecular epidemiology and clinical management implications.BMC microbiology · 2026Article
- Zoonotic Approach toInternational journal of microbiology · 2026Article
- Vaginal Colonization byInfection and drug resistance · 2026Article
- CRISPR1-mediated virulence and erythromycin resistance stabilization drives regional dominance ofFrontiers in cellular and infection microbiology · 2026Article
- Antibiotic Resistance and Serotypes Distribution inPolish journal of microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Streptococcus agalactiae (GBS) is a colonizing agent in pregnant women, the main cause of invasive neonatal infections, and the reason of serious diseases in non-pregnant adults. Several virulence determinants are involved in the pathogenesis. These include capsular polysaccharide, surface-localized proteins, and toxins. Penicillin is considered the first choice antibiotic for the treatment and prophylaxis; erythromycin, clindamycin and fluoroquinolones are recommended alternatives for penicillin-allergic GBS carriers or patients. Our objective was to investigate the virulence genetic characteristics and the antimicrobial susceptibility of 162 GBS colonizing and infective isolates recovered in Argentina. Serotypes Ia and III were the most prevalent ones, followed by Ib, II, V, IV and non-typeable. In relation to the 13 virulence genes screened, cpsA, cylE, hylB, lmb, and scpB were the most prevalent and could be postulated as vaccine epitopes; bca, rib, bac, hvgA, spb1, PI, PI-2a, and PI-2b were detected in lesser frequencies. No significant association was found between serotypes or virulence genes and colonizing or infective isolates but, on the contrary, significant association was observed between some genes and the most prevalent serotypes, la and III. The cluster analysis showed 52 virulence profiles and, antimicrobial resistance tests, 16 profiles, some with up to 4 resistances. Tetracycline resistance was significantly associated with colonizing isolates. Genes tetM and ermB conferring resistance to tetracyclines and macrolides, respectively, were the most commonly identified. Our findings show that GBS colonizing and infective isolates circulating in Argentina share similar features in terms of serotype and virulence genes and show a high level of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.